Healthcare Services

Cancer Gene Therapy Market Revenue Growth Expected to Reach $8.9 Billion by 2030 with 16.1% CAGR

March 30, 2026March 30, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The Cancer Gene Therapy Market From 2026 To 2030?

The cancer gene therapy market size has seen rapid expansion in recent years. It is anticipated to expand from $4.21 billion in 2025 to $4.9 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 16.4%. The historical rise in this market can be linked to advancements in molecular oncology research, an increase in clinical trials for gene therapy, elevated investment in biopharmaceutical research and development, regulatory endorsements of early gene therapies, and improved vector manufacturing capabilities.

The cancer gene therapy market size is anticipated to experience significant growth in the coming years. It is projected to expand to **$8.9 billion** by **2030**, achieving a compound annual growth rate (**CAGR**) of **16.1%**. This expansion during the forecast period is fueled by a heightened demand for personalized cancer treatments, increased investment in cell and gene therapy manufacturing, the wider deployment of next-generation viral vectors, an intensified focus on combination oncology therapies, and the growing embrace of precision oncology approaches. Noteworthy trends for the forecast period involve the accelerated development of targeted gene therapy platforms, the rising adoption of CAR-T and TCR therapies, a concentrated effort on optimizing viral vectors, the broadening availability of personalized cancer gene treatments, and enhanced integration of biomarker-guided therapy selection.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27233&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Cancer Gene Therapy Market?

The rising occurrence of cancer is anticipated to boost the expansion of the cancer gene therapy market in the future. Cancer is defined as a condition marked by the unchecked proliferation of abnormal cells, capable of invading and spreading throughout the body, originating in diverse tissues and organs, and categorized by its cell or tissue type of origin. The increase in cancer cases is linked to longer life expectancies, as the probability of developing cancer rises with age. Cancer gene therapy offers a treatment approach by altering or substituting defective genes to halt cancer cell development or improve the immune system’s capacity to eliminate them. For example, in August 2024, Macmillan Cancer Support, an organization located in the UK, stated that over 3 million individuals in the UK are currently living with cancer. This number is predicted to reach 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the growing incidence of cancer is propelling the growth of the cancer gene therapy market.

Which Segments Are Included In The Analysis Of The Cancer Gene Therapy Market?

The cancer gene therapy market covered in this report is segmented –

1) By Therapy: Gene Induced Immunotherapy, Oncolytic Virotherapy, Gene Transfer

2) By Indication: Large B-Cell Lymphoma, Multiple Myeloma, Acute Lymphoblastic Leukemia (ALL), Melanoma (lesions), Other Indications

3) By Vector Type: Lentivirus, RetroVirus And Gamma RetroVirus, Adeno-Associated Virus (AAV), Modified Herpes Simplex Virus, Adenovirus, Other Vector Types

4) By End-User: Hospitals, Research Institutes, Biopharma Companies, Cell Therapy Manufacturing Centers, Other End Users

Subsegments:

1) By Gene Induced Immunotherapy: CAR-T Cell Therapy, TCR (T-Cell Receptor) Therapy, Tumor-Infiltrating Lymphocyte (TIL) Therapy, Dendritic Cell-Based Gene Therapy, NK Cell Gene Therapy

2) By Oncolytic Virotherapy: Adenoviruses, Herpes Simplex Virus (HSV), Reovirus, Vaccinia Virus, Newcastle Disease Virus (NDV)

3) By Gene Transfer: Viral Gene Transfer, Non-Viral Gene Transfer

Which Trends Are Impacting The Growth Of The Cancer Gene Therapy Market?

Leading companies in the cancer gene therapy market are concentrating on creating advanced treatments, such as CAR-T cell therapy, to improve the precision of treatment, enhance patient results, and target cancer cells more efficiently while minimizing harm to healthy tissues. CAR-T therapy is a sophisticated immunotherapy where a patient’s immune cells are genetically modified to better detect and eliminate cancer cells by incorporating special receptors. For example, in April 2024, ImmunoACT, an India-based biotechnology firm, introduced NexCAR19 (actalycabtagene autoleucel), which is India’s first domestically developed CAR-T cell therapy for cancer. Specifically designed to treat B-cell lymphomas and leukemias, NexCAR19 functions by reprogramming a patient’s own T cells to identify and eradicate cancer cells. Leveraging advanced chimeric antigen receptor (CAR) technology, this therapy is manufactured locally, making it more affordable and accessible than imported options. This launch represents a significant milestone in India’s entry into the global cancer gene therapy domain, underscoring notable progress in domestic innovation and personalized cancer treatment.

Which Key Industry Participants Are Active In The Cancer Gene Therapy Market?

Major companies operating in the cancer gene therapy market are Bristol Myers Company, Novartis AG, GSK plc., Gilead Sciences Inc., Amgen Inc., Orchard Therapeutics Plc, AGC Biologics, Adaptimmune Limited, Sibiono, Elevate Bio Inc., Bluebird Bio Inc., Uniqure N.V., Shanghai Sunway Biotech Co. Ltd., Anges Inc., Gensight Biologics, Genelux Corporation, Cellectis, Abeona Therapeutics Inc., Kite Pharma Inc., Janssen Biotech Inc., Mustang Bio Inc., Intellia Therapeutics Inc., CRISPR Therapeutics AG, Caribou Biosciences Inc.

Read the full cancer gene therapy market report here:

https://www.thebusinessresearchcompany.com/report/cancer-gene-therapy-global-market-report

What Are The Leading Geographic Regions In The Cancer Gene Therapy Market?

North America was the largest region in the cancer gene therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Cancer Gene Therapy Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27233&type=smp

Browse Through More Reports Similar to the Global Cancer Gene Therapy Market 2026, By The Business Research Company

Cyclin Dependent Kinase Cdk 4 Or 6 Inhibitor Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/cyclin-dependent-kinase-cdk-4-or-6-inhibitor-drugs-global-market-report

Tyrosine Kinase Inhibitors Global Market Report

https://www.thebusinessresearchcompany.com/report/tyrosine-kinase-inhibitors-global-market-report

Janus Kinase Jak Inhibitors Global Market Report

https://www.thebusinessresearchcompany.com/report/janus-kinase-jak-inhibitors-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795